Rocconi, R.P.; Stanbery, L.; Madeira da Silva, L.; Barrington, R.A.; Aaron, P.; Manning, L.; Horvath, S.; Wallraven, G.; Bognar, E.; Walter, A.;
et al. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines 2021, 9, 894.
https://doi.org/10.3390/vaccines9080894
AMA Style
Rocconi RP, Stanbery L, Madeira da Silva L, Barrington RA, Aaron P, Manning L, Horvath S, Wallraven G, Bognar E, Walter A,
et al. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines. 2021; 9(8):894.
https://doi.org/10.3390/vaccines9080894
Chicago/Turabian Style
Rocconi, Rodney P., Laura Stanbery, Luciana Madeira da Silva, Robert A. Barrington, Phylicia Aaron, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Adam Walter,
and et al. 2021. "Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer" Vaccines 9, no. 8: 894.
https://doi.org/10.3390/vaccines9080894
APA Style
Rocconi, R. P., Stanbery, L., Madeira da Silva, L., Barrington, R. A., Aaron, P., Manning, L., Horvath, S., Wallraven, G., Bognar, E., Walter, A., & Nemunaitis, J.
(2021). Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines, 9(8), 894.
https://doi.org/10.3390/vaccines9080894
